Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Licitra L, et al. Among authors: esser r. Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19. Eur J Cancer. 2013. PMID: 23265711 Clinical Trial.
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.
Ciardiello F, Adams R, Tabernero J, Seufferlein T, Taieb J, Moiseyenko V, Ma B, Lopez G, Vansteenkiste JF, Esser R, Tejpar S. Ciardiello F, et al. Among authors: esser r. Oncologist. 2016 Mar;21(3):292-300. doi: 10.1634/theoncologist.2015-0279. Epub 2016 Feb 17. Oncologist. 2016. PMID: 26888693 Free PMC article.
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.
Bourhis J, Stein A, Paul de Boer J, Van Den Eynde M, Gold KA, Stintzing S, Becker JC, Moran M, Schroeder A, Pennock G, Salmio S, Esser R, Ciardiello F. Bourhis J, et al. Among authors: esser r. Cancer Treat Rev. 2021 Jun;97:102172. doi: 10.1016/j.ctrv.2021.102172. Epub 2021 Mar 2. Cancer Treat Rev. 2021. PMID: 33989949 Free article. Review.
Cetuximab every 2 weeks versus standard weekly dosing administration schedule.
Bokemeyer C, Ciardiello F, Dubreuil O, Guigay J, Kasper S, Pfeiffer P, Pinto C, Yamaguchi K, Yoshino T, Zielinski C, Esser R, Tabernero J. Bokemeyer C, et al. Among authors: esser r. Future Oncol. 2024 Mar;20(7):393-407. doi: 10.2217/fon-2023-0282. Epub 2023 Oct 18. Future Oncol. 2024. PMID: 37850363 Free article. Review.
Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer.
Kasper S, Foch C, Messinger D, Esser R, Lamy FX, Rothe V, Chen W, Cheng AL, Rouyer M, Brodowicz T, Zielinski C. Kasper S, et al. Among authors: esser r. Eur J Cancer. 2021 Feb;144:291-301. doi: 10.1016/j.ejca.2020.11.013. Epub 2020 Dec 28. Eur J Cancer. 2021. PMID: 33383349 Free article.
152 results